DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer
Interventions: DRUG: DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
Sponsor: Guangdong Provincial People's Hospital
Collaborators: Shantou Central Hospital|First Affiliated Hospital, Sun Yat-Sen University|Henan Cancer Hospital|Dongguan People's Hospital|Baotou Cancer Hospital